EURO11.SA
Coinvalores Dtvm Ltda.
São PauloBRLEQUITY
DELAYED
Last price
287.98
▼ 0.64 (0.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
288.65
Prev close
288.62
Day high
288.65
Day low
279.00
Volume
22
Market cap
—
P/E (TTM)
—
52W range
228.05 – 370.00
Day trading desk
Gap from prior close
+0.01%
Prior close 288.62
VWAP
284.05
+1.38% from price
Relative volume
—
—
Session range
3.46%
279.00 – 288.65
Position in range
93%
Near session high
ATR (14D)
11.25
3.91% of price
Prior day high
288.90
PDH
Prior day low
277.39
PDL
Bid / ask spread
—
Quote not published
Session volume
7
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.01%
-2.8%
1M
-9.16%
-12.5%
3M
-14.80%
-17.2%
6M
-11.92%
-23.8%
YTD
-4.01%
-16.0%
1Y
+24.60%
+4.5%
3Y
+16.13%
-58.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on EURO11.SA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $11.26M | $9.91M | $9.51M | $9.40M | — | +13.5% |
| Operating revenue | $11.26M | $9.91M | $9.51M | $9.40M | — | +13.5% |
| Cost of revenue | -$25.03M | $808.00K | -$3.76M | -$3.63M | — | -3,197.8% |
| Gross profit | $36.29M | $9.11M | $13.26M | $13.03M | — | +298.5% |
| Selling, general & admin | $1.31M | $190.00K | $130.00K | $162.00K | — | +591.1% |
| Total operating expense | $1.35M | $346.00K | $165.00K | $172.00K | — | +289.0% |
| Operating income | $34.94M | $8.76M | $13.10M | $12.86M | — | +298.9% |
| Net interest income | — | -$2.00K | $45.00K | $77.00K | $197.00K | — |
| Pre-tax income | $35.16M | $5.37M | $13.52M | $13.13M | — | +554.3% |
| Net income | $35.16M | $5.37M | $13.52M | $13.13M | — | +554.3% |
| Net income to common | $35.16M | $5.37M | $13.52M | $13.13M | — | +554.3% |
| Basic EPS | — | 14.00 | 35.21 | 34.20 | 46.72 | — |
| Diluted EPS | — | 14.00 | 35.21 | 34.20 | 46.72 | — |
| EBIT | $34.94M | $8.76M | $13.10M | $12.86M | — | +298.9% |
| EBITDA | $34.94M | $8.76M | $13.10M | $12.86M | — | +298.9% |
| Basic shares | — | 383.94K | 383.94K | 383.94K | 383.94K | — |
| Diluted shares | 383.94K | 383.94K | 383.94K | 383.94K | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.00K | $6.00K | $31.00K | $16.00K | +83.3% |
| Cash & short-term investments | $2.31M | $2.10M | $1.93M | $1.70M | +10.2% |
| Accounts receivable | $1.04M | $835.00K | $901.00K | $904.00K | +24.7% |
| Total current assets | $3.39M | $2.93M | $2.88M | $2.81M | +15.6% |
| Property, plant & equipment | $0 | $239.00K | $22.00K | $22.00K | -100.0% |
| Total assets | $156.98M | $129.74M | $132.43M | $127.42M | +21.0% |
| Total current liabilities | $1.93M | $1.42M | $1.40M | $1.60M | +36.1% |
| Total liabilities | $4.57M | $3.41M | $2.81M | $2.75M | +34.0% |
| Shareholder equity | $152.41M | $126.32M | $129.62M | $124.68M | +20.7% |
| Working capital | $1.46M | $1.51M | $1.48M | $1.21M | -3.6% |
| Net tangible assets | $152.41M | $126.32M | $129.62M | $124.68M | +20.7% |
| Shares issued | 383.94K | 383.94K | 383.94K | 383.94K | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Investing cash flow | -$246.00K | -$239.00K | -$204.00K | -$597.00K | -2.9% |
| Financing cash flow | -$8.98M | -$8.18M | -$8.51M | -$8.20M | -9.8% |
| Free cash flow | $9.49M | $9.04M | $8.95M | $8.68M | +5.1% |
| End cash position | $2.81M | $2.55M | $1.93M | $1.70M | +10.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
296.81
-2.98% from price
SMA 20
302.97
-4.95% from price
SMA 50
311.06
-7.42% from price
SMA 100
322.00
-10.57% from price
SMA 200
316.37
-8.97% from price
EMA 12
296.60
-2.91% from price
EMA 26
303.38
-5.08% from price
EMA 50
310.14
-7.14% from price
RSI (14)
28.8
Oversold
MACD (12,26,9)
-6.78
Hist -1.62
ATR (14)
11.25
3.91% of price
Realised vol 30D
20.3%
Annualised
Bollinger upper
320.22
20, 2σ
Bollinger lower
285.73
20, 2σ
50 / 200 cross
Death
311.06 vs 316.37
Trend bias
Below 200
-8.97%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.20
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
20.3%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-19.1%
Peak to trough
Max drawdown 5Y
-22.7%
Peak to trough
ATR 14
11.25
3.91% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
US vows 'economic asphyxiation' of Iran with new sanctions
AFP · 7m ago
Class Action Lawsuit Filed Against Utz Brands Over 'Avocado Oil' Boulder Canyon Potato Chips, Citing UC Davis Study on Avocado Oil Authenticity Testing
ACCESS Newswire · 11m ago
Why Trump's Canada tariffs are likely to have a modest impact on prices
CBS News · 11m ago
Trump announces 50% tariffs on Canadian automotive and steel imports
CBS News · 12m ago
Trade war of words intensifies between U.S., Canada
CBS News Videos · 14m ago
Hammond Manufacturing Company Limited Provides Update on Section 338 Tariffs
NewMediaWire · 14m ago
Top court upholds Trump bid to curb mail-in ballots for now
AFP · 14m ago
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
PR Newswire · 16m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.